Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
101.6 PLN | -0.59% | -0.39% | +5.94% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
Strengths
- The company is one of the best yield companies with high dividend expectations.
- Over the last 4 months, analysts have significantly revised upwards the company's estimated sales.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
- Historically, the company has been releasing figures that are above expectations.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 41.89 times its estimated earnings per share for the ongoing year.
- The valuation of the company is particularly high given the cash flows generated by its activity.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
Ratings chart - Surperformance
Sector: Specialty Chemicals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+5.94% | 504M | - | ||
+14.11% | 63.38B | A- | ||
-3.80% | 46.51B | A- | ||
+13.26% | 39.91B | B+ | ||
+19.57% | 25.57B | A- | ||
+8.22% | 18.95B | C+ | ||
-1.07% | 17.58B | B+ | ||
-21.03% | 16.1B | A- | ||
+1.06% | 14.98B | B+ | ||
-17.03% | 14.78B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- PCR Stock
- Ratings PCC Rokita SA